ACTIV evolving to meet COVID challenges

As hopes for a vaccine-led sprint to the end of the pandemic evaporate, the focus is widening to include therapeutics. Just as the expectation that one or two or even three jabs will end the crisis have turned out to be naïve, it is unrealistic to believe that a single drug or kind of drug will bring the crisis to an end.

While vaccines have received the lion’s share of U.S. government investment and attention, a parallel program has pooled resources of government, private industry and academic scientists to discover and evaluate potential therapeutics. ...